Department of Vascular Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Scottish Diabetes Research Network Epidemiology Group, Usher Institute, University of Edinburgh, Edinburgh, United Kingdom.
Clin J Am Soc Nephrol. 2022 Dec;17(12):1783-1791. doi: 10.2215/CJN.05020422. Epub 2022 Nov 4.
Individuals with type 2 diabetes are at a higher risk of developing kidney failure. The objective of this study was to develop and validate a decision support tool for estimating 10-year and lifetime risks of kidney failure in individuals with type 2 diabetes as well as estimating individual treatment effects of preventive medication.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The prediction algorithm was developed in 707,077 individuals with prevalent and incident type 2 diabetes from the Swedish National Diabetes Register for 2002-2019. Two Cox proportional regression functions for kidney failure (first occurrence of kidney transplantation, long-term dialysis, or persistent eGFR <15 ml/min per 1.73 m) and all-cause mortality as respective end points were developed using routinely available predictors. These functions were combined into life tables to calculate the predicted survival without kidney failure while using all-cause mortality as the competing outcome. The model was externally validated in 256,265 individuals with incident type 2 diabetes from the Scottish Care Information Diabetes database between 2004 and 2019.
During a median follow-up of 6.8 years (interquartile range, 3.2-10.6), 8004 (1%) individuals with type 2 diabetes in the Swedish National Diabetes Register cohort developed kidney failure, and 202,078 (29%) died. The model performed well, with statistics for kidney failure of 0.89 (95% confidence interval, 0.88 to 0.90) for internal validation and 0.74 (95% confidence interval, 0.73 to 0.76) for external validation. Calibration plots showed good agreement in observed versus predicted 10-year risk of kidney failure for both internal and external validation.
This study derived and externally validated a prediction tool for estimating 10-year and lifetime risks of kidney failure as well as life years free of kidney failure gained with preventive treatment in individuals with type 2 diabetes using easily available clinical predictors.
This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2022_11_04_CJN05020422.mp3.
2 型糖尿病患者发生肾衰竭的风险更高。本研究旨在开发和验证一种决策支持工具,用于估计 2 型糖尿病患者发生肾衰竭的 10 年和终生风险,以及估计预防药物治疗的个体效果。
设计、设置、参与者和测量方法:预测算法是在 2002 年至 2019 年期间,从瑞典国家糖尿病登记处的 707077 例现患和新发 2 型糖尿病患者中开发的。使用常规可用的预测因素,为肾衰竭(首次肾移植、长期透析或持续 eGFR <15 ml/min/1.73 m)和全因死亡率作为各自的终点,开发了两个 Cox 比例风险回归函数。这些函数被合并到生命表中,以计算无肾衰竭的预测生存率,同时将全因死亡率作为竞争结局。该模型在 2004 年至 2019 年期间苏格兰护理信息糖尿病数据库中 256265 例新发 2 型糖尿病患者中进行了外部验证。
在中位随访 6.8 年(四分位距 3.2-10.6)期间,瑞典国家糖尿病登记处队列中有 8004 例(1%)2 型糖尿病患者发生肾衰竭,202078 例(29%)死亡。该模型表现良好,内部验证的肾衰竭 C 统计量为 0.89(95%置信区间,0.88 至 0.90),外部验证为 0.74(95%置信区间,0.73 至 0.76)。校准图显示,内部和外部验证均显示出观察到的与预测的 10 年肾衰竭风险之间良好的一致性。
本研究使用易于获得的临床预测因素,从瑞典国家糖尿病登记处的 707077 例现患和新发 2 型糖尿病患者中推导并外部验证了一种预测工具,用于估计 2 型糖尿病患者发生肾衰竭的 10 年和终生风险,以及使用预防治疗获得的无肾衰竭生存年数。